A2A participated at the AI Applications Summit Biopharma discussing the urgency to advance AI applications in industry to bring benefits to patients faster
A2A Founder & CEO Edward Painter was a panelist at BIO Investor forum panel entitled "Applying artificial intelligence to improve therapy development today"